Pulike Biological Engineering, Inc. (603566.SS)
CNY 13.54
(-1.24%)
CNY 13.54
(-1.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 288.26 Million CNY | 14.15% |
| 2022 | 253.29 Million CNY | -19.21% |
| 2021 | 352.24 Million CNY | 5.38% |
| 2020 | 312.81 Million CNY | 85.26% |
| 2019 | 179.98 Million CNY | -16.07% |
| 2018 | 147.19 Million CNY | 60.38% |
| 2017 | 130.65 Million CNY | -35.14% |
| 2016 | 201.42 Million CNY | 11.38% |
| 2015 | 178.59 Million CNY | -6.44% |
| 2014 | 190 Million CNY | -12.11% |
| 2013 | 216.8 Million CNY | 22.39% |
| 2012 | 185.86 Million CNY | 31.27% |
| 2011 | 137.11 Million CNY | 40.78% |
| 2010 | 97.24 Million CNY | -13.94% |
| 2009 | 112.99 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 36.52 Million CNY | -62.69% |
| 2024 Q1 | 34.12 Million CNY | 8.6% |
| 2024 Q2 | 73.41 Million CNY | 56.01% |
| 2023 Q2 | 55.71 Million CNY | -29.43% |
| 2023 Q4 | -289.77 Thousand CNY | -100.32% |
| 2023 FY | - CNY | 14.15% |
| 2023 Q3 | 89.52 Million CNY | 60.69% |
| 2023 Q1 | 78.94 Million CNY | 69.49% |
| 2022 Q3 | 58.58 Million CNY | 10.55% |
| 2022 FY | - CNY | -19.21% |
| 2022 Q4 | 46.58 Million CNY | -20.49% |
| 2022 Q1 | 45.39 Million CNY | -10.8% |
| 2022 Q2 | 52.99 Million CNY | 16.75% |
| 2021 Q4 | 50.88 Million CNY | 14.0% |
| 2021 FY | - CNY | 5.38% |
| 2021 Q1 | 106.91 Million CNY | 10.03% |
| 2021 Q3 | 44.63 Million CNY | -45.17% |
| 2021 Q2 | 81.41 Million CNY | -23.85% |
| 2020 Q2 | 78.94 Million CNY | 24.22% |
| 2020 Q1 | 63.55 Million CNY | 271.74% |
| 2020 FY | - CNY | 85.26% |
| 2020 Q3 | 38.48 Million CNY | -51.25% |
| 2020 Q4 | 97.16 Million CNY | 152.49% |
| 2019 Q1 | 12 Million CNY | -77.91% |
| 2019 FY | - CNY | -16.07% |
| 2019 Q3 | 30.31 Million CNY | -52.96% |
| 2019 Q4 | 17.09 Million CNY | -43.61% |
| 2019 Q2 | 64.44 Million CNY | 436.92% |
| 2018 Q1 | 41.27 Million CNY | 123.68% |
| 2018 FY | - CNY | 60.38% |
| 2018 Q3 | 38.04 Million CNY | 5.61% |
| 2018 Q2 | 36.02 Million CNY | -12.71% |
| 2018 Q4 | 54.32 Million CNY | 42.79% |
| 2017 Q4 | 18.45 Million CNY | 31.99% |
| 2017 FY | - CNY | -35.14% |
| 2017 Q3 | 13.98 Million CNY | -46.21% |
| 2017 Q2 | 25.99 Million CNY | -27.0% |
| 2017 Q1 | 35.6 Million CNY | 32.5% |
| 2016 Q2 | 39.15 Million CNY | 29.16% |
| 2016 FY | - CNY | 11.38% |
| 2016 Q4 | 26.87 Million CNY | -62.5% |
| 2016 Q3 | 71.65 Million CNY | 83.02% |
| 2016 Q1 | 30.31 Million CNY | 51.43% |
| 2015 FY | - CNY | -6.44% |
| 2015 Q4 | 20.01 Million CNY | -63.94% |
| 2015 Q3 | 55.5 Million CNY | 200.6% |
| 2015 Q2 | -55.17 Million CNY | -142.57% |
| 2015 Q1 | 129.61 Million CNY | 540.26% |
| 2014 Q1 | 123.8 Million CNY | 0.0% |
| 2014 Q4 | 20.24 Million CNY | -73.48% |
| 2014 Q3 | 76.33 Million CNY | 229.82% |
| 2014 Q2 | -58.79 Million CNY | -147.49% |
| 2014 FY | - CNY | -12.11% |
| 2013 FY | - CNY | 22.39% |
| 2012 FY | - CNY | 31.27% |
| 2011 FY | - CNY | 40.78% |
| 2010 FY | - CNY | -13.94% |
| 2009 FY | - CNY | 0.0% |